Library Open Repository

Bertilimumab (Cambridge Antibody Technology Group)

Downloads

Downloads per month over past year

Ding, C and Li, J and Zhang, X (2004) Bertilimumab (Cambridge Antibody Technology Group). Current Opinion in Investigational Drugs, 5 (11). pp. 1213-1219. ISSN 1472-4472

[img] PDF
bertilimumab.pdf | Request a copy
Full text restricted
Available under University of Tasmania Standard License.

Abstract

Cambridge Antibody Technology (CAT) is developing bertilimumab, an anti-eotaxin-1 monoclonal antibody, for the potential treatment of allergic disorders. By September 2003, CAT had released results from phase I/II trials, and was seeking to outlicense rights for bertilimumab.

Item Type: Article
Journal or Publication Title: Current Opinion in Investigational Drugs
Page Range: pp. 1213-1219
ISSN: 1472-4472
Date Deposited: 01 Apr 2008 03:00
Last Modified: 18 Nov 2014 03:32
URI: http://eprints.utas.edu.au/id/eprint/3608
Item Statistics: View statistics for this item

Repository Staff Only (login required)

Item Control Page Item Control Page